Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.

HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Roche’s ipatasertib has improved progression-free survival in a sub-group of previously untreated metastatic castration-resistant prostate cancer patients – those whose tumors had PTEN loss – in a Phase III study. However the AKT inhibitor failed to cut the risk of disease worsening or death in the broader population.